WNT5A and B-cell chronic lymphocytic leukemia: Immunoblot analysis of lysates of CLL cells treated without or with recombinant Wnt5a and without or with zilovertamab revealed that Wnt5a treatment increased BCL-XL protein expression and that zilovertamab inhibited Wnt5a-induced increases in BCL-XL (Fig. 4B, C).